Contact: Cathia Falvey, (914) 740-2100, email@example.com
New Treatment Using Inhaled Interferon May Improve Lung Function
in Pulmonary Fibrosis
New Rochelle, NY, February 29, 2012— Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery, peer-reviewed journal from Mary Ann Liebert, Inc. The article on inhaled interferon-gamma is available free online at the Journal of Aerosol Medicine and Pulmonary Drug Delivery website.
Normally, systemic delivery of interferon-gamma can cause substantial side effects; however, delivery of aerosolized interferon-gamma directly into the lungs was shown to be safe and was associated with significantly reduced levels of profibrotic regulatory proteins. Keith Diaz, MD, Shibu Skaria, MD, Keith Harris, MD, Mario Solomita, DO, Stephanie Lau, MD, Kristy Bauer, MD, Gerald Smaldone, MD, PhD, and Rany Condos, MD, State University of New York, Stony Brook and New York University School of Medicine, NYC, show that inhalation of interferon-gamma in aerosol form three times a week for at least 80 weeks was well-tolerated by patients, with no systemic side effects.
The authors verified the presence of the drug in the material collected on lung washes and documented no change in the level of interferon-gamma in the blood during the treatment period. The report shows the results of pulmonary function tests, including forced vital capacity (FVC) and total lung capacity (TLC), and the effects of treatment on a six-minute walk test in the article entitled “Delivery and Safety of Inhaled Interferon-gamma in Idiopathic Pulmonary Fibrosis.”
“There is no treatment for Idiopathic Pulmonary Fibrosis, a disease usually fatal within 3-5 years,” says Gerald C. Smaldone, MD, PhD, Editor-in-Chief of the Journal and a coauthor of this article, and Professor and Chief, Division of Pulmonary and Critical Care Medicine at SUNY-Stony Brook. “The scientific community expected the injected form of interferon-gamma to help, but those studies failed. We have shown that inhaled interferon is safe with very high levels in the lungs. Now is the time to repeat the clinical trials with the inhaled form of this therapy.”
About the Journal
Journal of Aerosol Medicine and Pulmonary Drug Delivery is an authoritative peer-reviewed journal published bimonthly in print and online. It is the Official Publication of the International Society for Aerosols in Medicine.The Journal is the only authoritative publication delivering innovative articles on the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. Topics covered include airway reactivity and asthma treatment, inhalation of particles and gases in the respiratory tract, toxic effects of inhaled agents, and aerosols as tools for studying basic physiologic phenomena. Complete tables of content and a sample issue may be viewed on the Journal of Aerosol Medicine and Pulmonary Drug Delivery website.
About the Company
Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Pediatric Allergy, Immunology, and Pulmonology, High Altitude Medicine & Biology, and Microbial Drug Resistance. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available online at Mary Ann Liebert, Inc.